BiomX Inc (PHGE) 재무

BiomX, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. The company is headquartered in Dover, Delaware and currently employs 20 full-time employees. The company went IPO on 2018-12-18. Bacteriophage or phage are bacterial, species-specific, strain-limited viruses that infect, amplify and kill the target bacteria and are considered inert to mammalian cells. By utilizing proprietary combinations of naturally occurring phage and creating novel phage using synthetic biology, it develops phage-based therapies intended to address large-market diseases. The firm offers two phage-based product types: Fixed cocktail therapy and Personalized therapy. Its ongoing programs include BX011 and BX211. BX011 is a fixed multi-phage cocktail, for the treatment of DFI associated with Staphylococcus aureus (S. aureus). BX211 is a phage therapy for the treatment of Diabetic Foot Osteomyelitis (DFO) associated with S. aureus.